文献速递生殖医学

严重少精子症在接受胚胎非整倍体植入前遗传学检测的供卵ICSI周期中的临床影响

The clinical impact of oligozoospermia in oocyte donation ICSI cycles using preimplantation genetic test for aneuploidy.
PubMed 文献 · Hum Reprod · 2025-01-01

该回顾性观察队列研究纳入2017年1月至2023年12月欧洲多家诊所690个接受胚胎非整倍体植入前遗传学检测(PGT-A)的供卵ICSI周期,按精子浓度分为严重少精子症组(<5百万/ml,N=202)、中度少精子症组(5-16百万/ml,N=102)和正常精子对照组(≥16百万/ml,N=386)。结果显示严重少精子症组受精率显著降低、获卵裂期可活检囊胚数显著减少,但囊胚形成率、整倍体率、妊娠结局及累积活产率无显著差异;多因素分析未发现少精子症对非整倍体率、流产率或活产率的影响。

要点

  • 严重少精子症组精子活力显著低于中度少精子症组和对照组(P<0.0001)。
  • 严重少精子症组受精率显著低于中度少精子症组和对照组(P<0.01),但囊胚形成率无统计学差异。
  • 严重少精子症组获整倍体囊胚数显著减少(P=0.007),但单囊胚移植后妊娠、生化流产、临床流产及累积活产率均无显著差异。

核心结论

  • 在供卵ICSI联合PGT-A周期中,严重少精子症似乎不会显著影响囊胚发育后的IVF结局,与既往在控制较弱环境下的发现相矛盾。
  • 作者认为,在供卵背景下,男性因素不育本身并非进行PGT-A的指征。
  • 作者建议未来研究应在类似受控的供卵环境中探究其他严重受损的精子参数,以更好地理解父源胚胎非整倍体与IVF结局的关联。

研究设计与样本

  • 回顾性观察队列研究,纳入2017年1月至2023年12月欧洲多家诊所690个接受PGT-A的供卵IVF周期。
  • 按精子浓度分为三组:严重少精子症组(<5百万/ml,N=202)、中度少精子症组(5-16百万/ml,N=102)和正常精子对照组(≥16百万/ml,N=386)。
  • 所有周期均使用新鲜精液样本行ICSI,采用新鲜或冷冻供卵,所有囊胚活检行PGT-A,所有移植均为单囊胚移植,于玻璃化冷冻复苏后的后续周期进行。
  • 统计分析采用多因素回归模型评估少精子症率与临床、胚胎学及遗传学结局的相关性。

主要发现

  • 严重少精子症组精子活力显著低于中度少精子症组和对照组(P<0.0001)。
  • 严重少精子症组受精率显著低于中度少精子症组和对照组(P<0.01),但每受精卵的囊胚形成率无统计学差异。
  • 严重少精子症组获整倍体囊胚数显著减少(P=0.007),但单囊胚移植后妊娠率(P=0.37)、生化流产率(P=0.22)、临床流产率(P=0.86)及累积活产率(P=0.26)均无显著差异。
  • 多因素分析显示严重少精子症或中度少精子症对非整倍体率、流产率或活产率均无影响;PGT实验室策略与整倍体囊胚率相关(P<0.001),但对妊娠结局无显著影响。

临床怎么用

  • 作者认为,在供卵背景下,男性因素不育本身并非进行PGT-A的指征。
  • 作者指出,这些结果可为接受供卵治疗的夫妇提供 reassurance,即相关男性因素不育不会显著影响治疗结局。

局限性

  • 本研究为回顾性观察研究,聚焦于精子浓度降低相关的结局。
  • 严重男性因素不育的其他要素可能与结局有不同的关联。
  • 未考虑可能影响精子质量的潜在混杂因素,包括男性生活方式因素。
  • 作者指出,未来需在类似受控的供卵环境中开展进一步研究,以探究其他严重受损的精子参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do severely impaired sperm concentrations (oligozoospemia) in male factor infertility affect embryo aneuploidy rates and clinical results after IVF oocyte donation cycles? SUMMARY ANSWER: Severe oligozoospermia (SO) in IVF cycles utilizing donor oocytes does not significantly affect embryo euploidy rates or IVF outcomes or cumulative live birth rates (CLBRs). WHAT IS KNOWN ALREADY: SO has previously been linked to elevated rates of chromosomal abnormalities in spermatozoa and altered rates of embryo development with poorer reproductive outcomes. Nonetheless, the precise impacts of severe male factor infertility on embryonic aneuploidy rates and the success of IVF, in the context of controlled female ages in oocyte donation cycles with preimplantation genetic testing for aneuploidy (PGT-A), are still not fully understood. STUDY DESIGN, SIZE, DURATION: This retrospective observational cohort study involved 690 IVF oocyte donation cycles undergoing PGT-A from multiple clinics across Europe between January 2017 and December 2023. The study population was divided into three groups based on sperm concentration: SO (<5 million sperm/ml), moderate oligozoospermia (MO, 5-16 million sperm/ml), and a normozoospermia control group (≥16 million sperm/ml) for outcome analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: The IVF outcomes and variables for couples undergoing oocyte donor cycles were investigated. ICSI was performed in all cycles using fresh sperm samples that were assessed for standard semen parameters with fresh or frozen donated oocytes. All of the resulting embryos were biopsied at the blastocyst stage for PGT-A, and all transfers were of single embryos performed in subsequent cycles after vitrification and warming. Statistical analysis was performed using multivariate regression models to identify correlations between rates of oligozoospermia and clinical, embryological and genetic outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: The study included 690 couples, in the SO (N = 202), MO (N = 102), and the control normozoospermia (N = 386) groups. The SO group had significantly lower sperm motility (P < 0.0001) and significantly reduced fertilization rates compared to the MO and control groups (P < 0.01). However, no statistical difference was observed for the blastocyst formation rate (per fertilized oocyte). Mostly due to the reduced fertilization rates, the number of euploid blastocysts obtained was significantly lower in the SO group (P = 0.007), however, this did not affect the pregnancy, biochemical or clinical miscarriage (P = 0.37, P = 0.22, and P = 0.86), or CLBRs (P = 0.26) after single blastocyst transfers. The multivariate analysis showed no effect of SO or MO on aneuploidy, miscarriage, or live birth rates. Interestingly, the PGT laboratory strategy (<0.001) was associated with the rate of euploid blastocysts but had no significant effect on pregnancy outcomes. LIMITATIONS, REASONS FOR CAUTION: This is a retrospective observational study focusing on outcomes associated with reduced sperm concentration. Other elements of severe male factor infertility may have different associations with outcomes. Also, potential confounding factors including male lifestyle factors that can influence sperm quality were not considered. WIDER IMPLICATIONS OF THE FINDINGS: In this oocyte donation setting, we demonstrated that SO is unlikely to significantly affect IVF outcomes following blastocyst development, which contradicts previous findings in less controlled settings. This suggests that male factor infertility in the setting of oocyte donation is not an indication per se to perform PGT-A. These results provide reassurance for couples when undergoing treatment with oocyte donation that any related male factor infertility will not significantly impact treatment outcomes. Further research should use similar controlled oocyte donation settings to investigate other severely impaired sperm parameters to better understand associations with paternal embryonic aneuploidy and IVF outcomes, guiding a more informed path for male factor infertility treatment. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used and the authors have no conflicting interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cozzolino M, Pellegrini L, Ottolini CS, et al. The clinical impact of oligozoospermia in oocyte donation ICSI cycles using preimplantation genetic test for aneuploidy. Hum Reprod. 2025. PMID: 40359305. doi:10.1093/humrep/deaf080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。